A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation
This single-center retrospective study was performed in consecutive patients with acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic cell transplantation (HCT) and received salvage therapy using inotuzumab ozogamicin (InO). Ten patients (median age: 27 years) treated between Ju...
Saved in:
| Published in | International journal of hematology Vol. 115; no. 1; pp. 69 - 76 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Singapore
Springer Singapore
01.01.2022
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0925-5710 1865-3774 1865-3774 |
| DOI | 10.1007/s12185-021-03217-4 |
Cover
Loading…
| Abstract | This single-center retrospective study was performed in consecutive patients with acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic cell transplantation (HCT) and received salvage therapy using inotuzumab ozogamicin (InO). Ten patients (median age: 27 years) treated between June 2018 and July 2020 who met the eligibility criteria were included in this study. Nine patients received InO in one cycle and seven of these patients achieved complete hematological remission after salvage chemotherapy including InO. Negative minimal residual disease was confirmed in all four evaluable patients. Eight patients were successfully bridged to the subsequent HCT. After HCT, veno-occlusive disease (VOD) developed in three patients, and caused the death of one. No patient received maintenance therapy. At present, five patients are disease-free and alive, and the overall and progression-free survival rates at 1 year were 60% and 40%, respectively. High rates of disease remission and bridging to HCT with comprehensive treatments including InO may have contributed to favorable outcomes. However, further investigation is needed to reduce post-HCT complications including VOD. |
|---|---|
| AbstractList | This single-center retrospective study was performed in consecutive patients with acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic cell transplantation (HCT) and received salvage therapy using inotuzumab ozogamicin (InO). Ten patients (median age: 27 years) treated between June 2018 and July 2020 who met the eligibility criteria were included in this study. Nine patients received InO in one cycle and seven of these patients achieved complete hematological remission after salvage chemotherapy including InO. Negative minimal residual disease was confirmed in all four evaluable patients. Eight patients were successfully bridged to the subsequent HCT. After HCT, veno-occlusive disease (VOD) developed in three patients, and caused the death of one. No patient received maintenance therapy. At present, five patients are disease-free and alive, and the overall and progression-free survival rates at 1 year were 60% and 40%, respectively. High rates of disease remission and bridging to HCT with comprehensive treatments including InO may have contributed to favorable outcomes. However, further investigation is needed to reduce post-HCT complications including VOD. This single-center retrospective study was performed in consecutive patients with acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic cell transplantation (HCT) and received salvage therapy using inotuzumab ozogamicin (InO). Ten patients (median age: 27 years) treated between June 2018 and July 2020 who met the eligibility criteria were included in this study. Nine patients received InO in one cycle and seven of these patients achieved complete hematological remission after salvage chemotherapy including InO. Negative minimal residual disease was confirmed in all four evaluable patients. Eight patients were successfully bridged to the subsequent HCT. After HCT, veno-occlusive disease (VOD) developed in three patients, and caused the death of one. No patient received maintenance therapy. At present, five patients are disease-free and alive, and the overall and progression-free survival rates at 1 year were 60% and 40%, respectively. High rates of disease remission and bridging to HCT with comprehensive treatments including InO may have contributed to favorable outcomes. However, further investigation is needed to reduce post-HCT complications including VOD. This single-center retrospective study was performed in consecutive patients with acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic cell transplantation (HCT) and received salvage therapy using inotuzumab ozogamicin (InO). Ten patients (median age: 27 years) treated between June 2018 and July 2020 who met the eligibility criteria were included in this study. Nine patients received InO in one cycle and seven of these patients achieved complete hematological remission after salvage chemotherapy including InO. Negative minimal residual disease was confirmed in all four evaluable patients. Eight patients were successfully bridged to the subsequent HCT. After HCT, veno-occlusive disease (VOD) developed in three patients, and caused the death of one. No patient received maintenance therapy. At present, five patients are disease-free and alive, and the overall and progression-free survival rates at 1 year were 60% and 40%, respectively. High rates of disease remission and bridging to HCT with comprehensive treatments including InO may have contributed to favorable outcomes. However, further investigation is needed to reduce post-HCT complications including VOD.This single-center retrospective study was performed in consecutive patients with acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic cell transplantation (HCT) and received salvage therapy using inotuzumab ozogamicin (InO). Ten patients (median age: 27 years) treated between June 2018 and July 2020 who met the eligibility criteria were included in this study. Nine patients received InO in one cycle and seven of these patients achieved complete hematological remission after salvage chemotherapy including InO. Negative minimal residual disease was confirmed in all four evaluable patients. Eight patients were successfully bridged to the subsequent HCT. After HCT, veno-occlusive disease (VOD) developed in three patients, and caused the death of one. No patient received maintenance therapy. At present, five patients are disease-free and alive, and the overall and progression-free survival rates at 1 year were 60% and 40%, respectively. High rates of disease remission and bridging to HCT with comprehensive treatments including InO may have contributed to favorable outcomes. However, further investigation is needed to reduce post-HCT complications including VOD. |
| Author | Nakajima, Hideaki Tachibana, Takayoshi Izumi, Akihiko Tanaka, Masatsugu Ando, Taiki Kanamori, Heiwa |
| Author_xml | – sequence: 1 givenname: Akihiko surname: Izumi fullname: Izumi, Akihiko organization: Department of Hematology, Kanagawa Cancer Center – sequence: 2 givenname: Takayoshi orcidid: 0000-0002-7780-4459 surname: Tachibana fullname: Tachibana, Takayoshi email: tcbn@kcch.jp organization: Department of Hematology, Kanagawa Cancer Center – sequence: 3 givenname: Taiki surname: Ando fullname: Ando, Taiki organization: Department of Hematology, Kanagawa Cancer Center – sequence: 4 givenname: Masatsugu surname: Tanaka fullname: Tanaka, Masatsugu organization: Department of Hematology, Kanagawa Cancer Center – sequence: 5 givenname: Heiwa surname: Kanamori fullname: Kanamori, Heiwa organization: Department of Hematology, Kanagawa Cancer Center – sequence: 6 givenname: Hideaki surname: Nakajima fullname: Nakajima, Hideaki organization: Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34490598$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kcFu1DAQhi1URLeFF-CALHHhEvDEdrI5VhVQpEpc4BxNvJNdF8cOtiPUPgpPi7cpIPXQ01y-b-bX_GfsxAdPjL0G8R6EaD8kqGGrK1FDJWQNbaWesQ1sG13JtlUnbCO6Wle6BXHKzlK6EQJaodoX7FQq1QndbTfs9wU3mIgnipYSDyOfMVvyOfEcCTPt-C-bD9z6kJe7ZcKBh7uwx8ka6_kYIkezZOLudpoPYXCYsjXc0fKDJos8ksM5lSU4Ziqsc2FPngpyoAlzmIOlo2DIuXIQfZod-lwiBP-SPR_RJXr1MM_Z908fv11eVddfP3-5vLiujOy6XMEOB0TsSOpaGQKSAsywQ2iN0iMaPYjaGCG2zY5IgGoMKKM7qEcSjdFanrN36945hp8LpdxPNh0DoaewpL7WrQAAKbuCvn2E3oQl-pKurxvoukbpVhbqzQO1DBPt-jnaCeNt__frBahXwMSQUqTxHwKiP1bbr9X2pdr-vtpeFWn7SDJ2fVT5m3VPq3JVU7nj9xT_x37C-gOkxLvr |
| CitedBy_id | crossref_primary_10_1080_17474086_2022_2125375 crossref_primary_10_1007_s40278_022_16899_9 crossref_primary_10_1007_s12185_022_03377_x crossref_primary_10_3389_fonc_2023_1047554 |
| Cites_doi | 10.2169/internalmedicine.4440-20 10.1016/S2352-3026(17)30103-5 10.1182/blood-2003-01-0255 10.1056/NEJMoa1609783 10.1038/bmt.2016.130 10.1002/cncr.31720 10.1007/s12185-019-02749-0 10.1002/cncr.31317 10.1182/blood-2006-01-015347 10.1038/sj.leu.2402922 10.3390/curroncol28010027 10.1016/j.bbmt.2019.12.763 10.1056/NEJMoa1509277 10.1002/ajh.23901 10.1111/bjh.12225 10.1016/j.bbmt.2019.02.018 10.1038/bmt.2015.52 10.1182/blood-2011-12-399287 10.1080/10428194.2016.1243678 10.1056/NEJMoa1306494 10.1002/cncr.30130 10.1038/leu.2011.351 10.1002/cncr.32116 10.1182/blood-2015-10-676924 10.1056/NEJMoa1407222 10.1158/1078-0432.CCR-20-2399 10.1111/cas.14167 10.1007/978-1-60761-629-0_13 10.1001/jamaoncol.2017.2380 |
| ContentType | Journal Article |
| Copyright | Japanese Society of Hematology 2021 2021. Japanese Society of Hematology. Japanese Society of Hematology 2021. |
| Copyright_xml | – notice: Japanese Society of Hematology 2021 – notice: 2021. Japanese Society of Hematology. – notice: Japanese Society of Hematology 2021. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7T5 7T7 7TM 7X7 7XB 88E 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA BENPR C1K CCPQU FR3 FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1007/s12185-021-03217-4 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Medical Database Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Technology Research Database ProQuest One Academic Middle East (New) Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Technology Research Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1865-3774 |
| EndPage | 76 |
| ExternalDocumentID | 34490598 10_1007_s12185_021_03217_4 |
| Genre | Journal Article |
| GroupedDBID | --- --K -5E -5G -BR -EM -Y2 -~C .55 .86 .VR 06C 06D 0R~ 0VY 1B1 1N0 203 29J 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2~H 30V 3V. 4.4 406 408 40D 40E 53G 5GY 5VS 67Z 6NX 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHQN ABIPD ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACDTI ACGFO ACGFS ACHSB ACHVE ACHXU ACIHN ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACREN ACZOJ ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEAQA AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFKRA AFLOW AFQWF AFRAH AFWTZ AFYQB AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BDATZ BENPR BGNMA BKEYQ BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG EX3 F5P FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 H13 HF~ HG5 HG6 HLICF HMCUK HMJXF HRMNR HZ~ IHE IJ- IKXTQ IMOTQ IWAJR IXC IXD IZQ I~X I~Z J-C J0Z JBSCW JZLTJ KOV KPH LLZTM M1P M41 M4Y MA- N9A NAPCQ NPVJJ NQ- NQJWS NU0 O9- O93 O9I O9J P2P P9S PF0 PQQKQ PROAC PSQYO PT4 Q2X QOR QOS R89 R9I RIG ROL RPX RPZ RSV S16 S1Z S27 S37 S3B SAP SDH SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TT1 TUC U2A U9L UDS UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W48 WJK WK8 WOW X7M YLTOR Z45 Z7U Z81 Z82 Z87 ZMTXR ZOVNA ZXP AAPKM AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC AEZWR AFDZB AFHIU AFOHR AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7T5 7T7 7TM 7XB 8FD 8FK ABRTQ C1K FR3 H94 K9. P64 PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c399t-1dabaaa9e3524ce1e301cbda17c45fac5b02cc0086dee0146c14c5912fe06c553 |
| IEDL.DBID | U2A |
| ISSN | 0925-5710 1865-3774 |
| IngestDate | Mon Jul 21 11:29:02 EDT 2025 Fri Aug 22 03:12:09 EDT 2025 Wed Feb 19 02:26:45 EST 2025 Thu Apr 24 22:53:36 EDT 2025 Tue Jul 01 03:48:03 EDT 2025 Fri Feb 21 02:46:40 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Acute lymphoblastic leukemia Transplantation Inotuzumab ozogamicin |
| Language | English |
| License | 2021. Japanese Society of Hematology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c399t-1dabaaa9e3524ce1e301cbda17c45fac5b02cc0086dee0146c14c5912fe06c553 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-7780-4459 |
| PMID | 34490598 |
| PQID | 2619964573 |
| PQPubID | 55446 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_2570111339 proquest_journals_2619964573 pubmed_primary_34490598 crossref_primary_10_1007_s12185_021_03217_4 crossref_citationtrail_10_1007_s12185_021_03217_4 springer_journals_10_1007_s12185_021_03217_4 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20220100 2022-01-00 2022-Jan 20220101 |
| PublicationDateYYYYMMDD | 2022-01-01 |
| PublicationDate_xml | – month: 1 year: 2022 text: 20220100 |
| PublicationDecade | 2020 |
| PublicationPlace | Singapore |
| PublicationPlace_xml | – name: Singapore – name: Japan – name: Tokyo |
| PublicationTitle | International journal of hematology |
| PublicationTitleAbbrev | Int J Hematol |
| PublicationTitleAlternate | Int J Hematol |
| PublicationYear | 2022 |
| Publisher | Springer Singapore Springer Nature B.V |
| Publisher_xml | – name: Springer Singapore – name: Springer Nature B.V |
| References | Spyridonidis, Labopin, Schmid, Volin, Yakoub-Agha, Stadler (CR1) 2012; 26 Okura, Ida, Yamauchi (CR11) 2020; 59 Jabbour, Ravandi, Kebriaei, Huang, Short, Thomas (CR16) 2018; 4 Kantarjian, DeAngelo, Stelljes, Liedtke, Stock, Gökbuget (CR5) 2019; 125 Fingrut, Davis, McGinnis, Dallas, Ramadan, Merkeley (CR20) 2020; 28 Akahoshi, Nishiwaki, Mizuta, Ohashi, Uchida, Tanaka (CR29) 2019; 110 Kako, Kanamori, Kobayashi, Shigematsu, Nannya, Nakamae (CR3) 2013; 161 Gökbuget, Stanze, Beck, Diedrich, Horst, Hüttmann (CR2) 2012; 120 Wadleigh, Richardson, Zahrieh, Lee, Cutler, Ho (CR26) 2003; 102 Fan, Robetorye (CR12) 2010; 630 Jabbour, Sasaki, Ravandi, Huang, Short, Khouri (CR17) 2018; 124 Giebel, Czyz, Ottmann, Baron, Brissot, Ciceri (CR28) 2016; 122 Ray, Cowan-Jacob, Manley, Mestan, Griffin (CR14) 2007; 109 Mohty, Malard, Abecassis, Aerts, Alaskar, Aljurf (CR15) 2016; 51 Kantarjian, DeAngelo, Advani, Stelljes, Kebriaei, Cassaday (CR9) 2017; 4 Corbacioglu, Jabbour, Mohty (CR24) 2019; 25 Kantarjian, Su, Jabbour, Bhattacharyya, Yan, Cappelleri (CR21) 2018; 124 Richardson, Riches, Kernan, Brochstein, Mineishi, Termuhlen (CR25) 2016; 127 Kantarjian, Stein, Gökbuget, Fielding, Schuh, Ribera (CR6) 2017; 376 Cortes, Kim, Pinilla-Ibarz, le Coutre, Paquette, Chuah (CR8) 2013; 369 Jabbour, O'Brien, Huang, Thomas, Rytting, Sasaki (CR18) 2015; 90 Maude, Frey, Shaw, Aplenc, Barrett, Bunin (CR7) 2014; 371 Ho, Martin, Pérez, Steinert, Zhang, Chirnomas (CR27) 2020; 26 Mohty, Malard, Abecassis, Aerts, Alaskar, Aljurf (CR23) 2015; 50 Fujishima, Uchida, Onishi, Jung, Goh, Ando (CR10) 2019; 110 Tachibana, Matsumoto, Tanaka, Hagihara, Motohashi, Yamamoto (CR22) 2017; 58 Kantarjian, Stock, Cassaday, DeAngelo, Jabbour, O'Brien (CR19) 2021; 27 van der Velden, Hochhaus, Cazzaniga, Szczepanski, Gabert, van Dongen (CR13) 2003; 17 Kantarjian, DeAngelo, Stelljes, Martinelli, Liedtke, Stock (CR4) 2016; 375 HM Kantarjian (3217_CR4) 2016; 375 M Wadleigh (3217_CR26) 2003; 102 M Mohty (3217_CR23) 2015; 50 S Giebel (3217_CR28) 2016; 122 W Fingrut (3217_CR20) 2020; 28 A Spyridonidis (3217_CR1) 2012; 26 M Mohty (3217_CR15) 2016; 51 T Tachibana (3217_CR22) 2017; 58 N Gökbuget (3217_CR2) 2012; 120 HM Kantarjian (3217_CR21) 2018; 124 H Kantarjian (3217_CR6) 2017; 376 Y Akahoshi (3217_CR29) 2019; 110 HM Kantarjian (3217_CR19) 2021; 27 VH van der Velden (3217_CR13) 2003; 17 S Corbacioglu (3217_CR24) 2019; 25 E Jabbour (3217_CR18) 2015; 90 HM Kantarjian (3217_CR9) 2017; 4 VT Ho (3217_CR27) 2020; 26 M Okura (3217_CR11) 2020; 59 N Fujishima (3217_CR10) 2019; 110 JE Cortes (3217_CR8) 2013; 369 A Ray (3217_CR14) 2007; 109 PG Richardson (3217_CR25) 2016; 127 S Kako (3217_CR3) 2013; 161 HM Kantarjian (3217_CR5) 2019; 125 E Jabbour (3217_CR16) 2018; 4 E Jabbour (3217_CR17) 2018; 124 SL Maude (3217_CR7) 2014; 371 H Fan (3217_CR12) 2010; 630 |
| References_xml | – volume: 59 start-page: 2047 issue: 16 year: 2020 end-page: 2051 ident: CR11 article-title: Clinical significance of inotuzumab ozogamicin in non-transplant patients with relapsed acute lymphoblastic leukemia: a report of four cases publication-title: Intern Med doi: 10.2169/internalmedicine.4440-20 – volume: 4 start-page: e387 issue: 8 year: 2017 end-page: e398 ident: CR9 article-title: Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study publication-title: Lancet Haematol doi: 10.1016/S2352-3026(17)30103-5 – volume: 102 start-page: 1578 issue: 5 year: 2003 end-page: 1582 ident: CR26 article-title: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation publication-title: Blood doi: 10.1182/blood-2003-01-0255 – volume: 376 start-page: 836 issue: 9 year: 2017 end-page: 847 ident: CR6 article-title: Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia publication-title: N Engl J Med doi: 10.1056/NEJMoa1609783 – volume: 51 start-page: 906 issue: 7 year: 2016 end-page: 912 ident: CR15 article-title: Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation publication-title: Bone Marrow Transplant doi: 10.1038/bmt.2016.130 – volume: 124 start-page: 4044 issue: 20 year: 2018 end-page: 4055 ident: CR17 article-title: Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage publication-title: Cancer doi: 10.1002/cncr.31720 – volume: 110 start-page: 709 issue: 6 year: 2019 end-page: 722 ident: CR10 article-title: Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia publication-title: Int J Hematol doi: 10.1007/s12185-019-02749-0 – volume: 124 start-page: 2151 issue: 10 year: 2018 end-page: 2160 ident: CR21 article-title: Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia publication-title: Cancer doi: 10.1002/cncr.31317 – volume: 109 start-page: 5011 issue: 11 year: 2007 end-page: 5015 ident: CR14 article-title: Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study publication-title: Blood doi: 10.1182/blood-2006-01-015347 – volume: 17 start-page: 1013 issue: 6 year: 2003 end-page: 1034 ident: CR13 article-title: Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects publication-title: Leukemia doi: 10.1038/sj.leu.2402922 – volume: 28 start-page: 252 issue: 1 year: 2020 end-page: 259 ident: CR20 article-title: Reevaluating patient eligibility for inotuzumab ozogamicin based on CD22 expression: is dim expression sufficient? publication-title: Curr Oncol doi: 10.3390/curroncol28010027 – volume: 26 start-page: 884 issue: 5 year: 2020 end-page: 892 ident: CR27 article-title: Prior Gemtuzumab ozogamicin exposure in adults with acute myeloid leukemia does not increase hepatic veno-occlusive disease risk after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research analysis publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2019.12.763 – volume: 375 start-page: 740 issue: 8 year: 2016 end-page: 753 ident: CR4 article-title: Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia publication-title: N Engl J Med doi: 10.1056/NEJMoa1509277 – volume: 90 start-page: 193 issue: 3 year: 2015 end-page: 196 ident: CR18 article-title: Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody publication-title: Am J Hematol doi: 10.1002/ajh.23901 – volume: 161 start-page: 95 issue: 1 year: 2013 end-page: 103 ident: CR3 article-title: Outcome after first relapse in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia publication-title: Br J Haematol doi: 10.1111/bjh.12225 – volume: 25 start-page: 1271 issue: 7 year: 2019 end-page: 1280 ident: CR24 article-title: Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2019.02.018 – volume: 50 start-page: 781 issue: 6 year: 2015 end-page: 789 ident: CR23 article-title: Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT) publication-title: Bone Marrow Transplant doi: 10.1038/bmt.2015.52 – volume: 120 start-page: 2032 issue: 10 year: 2012 end-page: 2041 ident: CR2 article-title: Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation publication-title: Blood doi: 10.1182/blood-2011-12-399287 – volume: 58 start-page: 1403 issue: 6 year: 2017 end-page: 1411 ident: CR22 article-title: Outcome and prognostic factors among patients who underwent a second transplantation for disease relapse post the first allogeneic cell transplantation publication-title: Leuk Lymphoma doi: 10.1080/10428194.2016.1243678 – volume: 369 start-page: 1783 issue: 19 year: 2013 end-page: 1796 ident: CR8 article-title: Phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias publication-title: N Engl J Med doi: 10.1056/NEJMoa1306494 – volume: 122 start-page: 2941 issue: 19 year: 2016 end-page: 2951 ident: CR28 article-title: Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation publication-title: Cancer doi: 10.1002/cncr.30130 – volume: 26 start-page: 1211 issue: 6 year: 2012 end-page: 1217 ident: CR1 article-title: Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT publication-title: Leukemia doi: 10.1038/leu.2011.351 – volume: 125 start-page: 2474 issue: 14 year: 2019 end-page: 2487 ident: CR5 article-title: Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study publication-title: Cancer doi: 10.1002/cncr.32116 – volume: 127 start-page: 1656 issue: 13 year: 2016 end-page: 1665 ident: CR25 article-title: Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure publication-title: Blood doi: 10.1182/blood-2015-10-676924 – volume: 371 start-page: 1507 issue: 16 year: 2014 end-page: 1517 ident: CR7 article-title: Chimeric antigen receptor T cells for sustained remissions in leukemia publication-title: N Engl J Med doi: 10.1056/NEJMoa1407222 – volume: 27 start-page: 2742 issue: 10 year: 2021 end-page: 2754 ident: CR19 article-title: Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in the INO-VATE trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-20-2399 – volume: 110 start-page: 3255 issue: 10 year: 2019 end-page: 3256 ident: CR29 article-title: Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia publication-title: Cancer Sci doi: 10.1111/cas.14167 – volume: 630 start-page: 199 year: 2010 end-page: 213 ident: CR12 article-title: Real-time quantitative reverse transcriptase polymerase chain reaction publication-title: Methods Mol Biol doi: 10.1007/978-1-60761-629-0_13 – volume: 4 start-page: 230 issue: 2 year: 2018 end-page: 234 ident: CR16 article-title: Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper-CVD for patients with relapsed or refractory philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2017.2380 – volume: 369 start-page: 1783 issue: 19 year: 2013 ident: 3217_CR8 publication-title: N Engl J Med doi: 10.1056/NEJMoa1306494 – volume: 375 start-page: 740 issue: 8 year: 2016 ident: 3217_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa1509277 – volume: 127 start-page: 1656 issue: 13 year: 2016 ident: 3217_CR25 publication-title: Blood doi: 10.1182/blood-2015-10-676924 – volume: 376 start-page: 836 issue: 9 year: 2017 ident: 3217_CR6 publication-title: N Engl J Med doi: 10.1056/NEJMoa1609783 – volume: 109 start-page: 5011 issue: 11 year: 2007 ident: 3217_CR14 publication-title: Blood doi: 10.1182/blood-2006-01-015347 – volume: 26 start-page: 884 issue: 5 year: 2020 ident: 3217_CR27 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2019.12.763 – volume: 17 start-page: 1013 issue: 6 year: 2003 ident: 3217_CR13 publication-title: Leukemia doi: 10.1038/sj.leu.2402922 – volume: 124 start-page: 4044 issue: 20 year: 2018 ident: 3217_CR17 publication-title: Cancer doi: 10.1002/cncr.31720 – volume: 630 start-page: 199 year: 2010 ident: 3217_CR12 publication-title: Methods Mol Biol doi: 10.1007/978-1-60761-629-0_13 – volume: 4 start-page: 230 issue: 2 year: 2018 ident: 3217_CR16 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2017.2380 – volume: 58 start-page: 1403 issue: 6 year: 2017 ident: 3217_CR22 publication-title: Leuk Lymphoma doi: 10.1080/10428194.2016.1243678 – volume: 102 start-page: 1578 issue: 5 year: 2003 ident: 3217_CR26 publication-title: Blood doi: 10.1182/blood-2003-01-0255 – volume: 120 start-page: 2032 issue: 10 year: 2012 ident: 3217_CR2 publication-title: Blood doi: 10.1182/blood-2011-12-399287 – volume: 59 start-page: 2047 issue: 16 year: 2020 ident: 3217_CR11 publication-title: Intern Med doi: 10.2169/internalmedicine.4440-20 – volume: 28 start-page: 252 issue: 1 year: 2020 ident: 3217_CR20 publication-title: Curr Oncol doi: 10.3390/curroncol28010027 – volume: 50 start-page: 781 issue: 6 year: 2015 ident: 3217_CR23 publication-title: Bone Marrow Transplant doi: 10.1038/bmt.2015.52 – volume: 4 start-page: e387 issue: 8 year: 2017 ident: 3217_CR9 publication-title: Lancet Haematol doi: 10.1016/S2352-3026(17)30103-5 – volume: 110 start-page: 709 issue: 6 year: 2019 ident: 3217_CR10 publication-title: Int J Hematol doi: 10.1007/s12185-019-02749-0 – volume: 124 start-page: 2151 issue: 10 year: 2018 ident: 3217_CR21 publication-title: Cancer doi: 10.1002/cncr.31317 – volume: 27 start-page: 2742 issue: 10 year: 2021 ident: 3217_CR19 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-20-2399 – volume: 51 start-page: 906 issue: 7 year: 2016 ident: 3217_CR15 publication-title: Bone Marrow Transplant doi: 10.1038/bmt.2016.130 – volume: 122 start-page: 2941 issue: 19 year: 2016 ident: 3217_CR28 publication-title: Cancer doi: 10.1002/cncr.30130 – volume: 125 start-page: 2474 issue: 14 year: 2019 ident: 3217_CR5 publication-title: Cancer doi: 10.1002/cncr.32116 – volume: 371 start-page: 1507 issue: 16 year: 2014 ident: 3217_CR7 publication-title: N Engl J Med doi: 10.1056/NEJMoa1407222 – volume: 25 start-page: 1271 issue: 7 year: 2019 ident: 3217_CR24 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2019.02.018 – volume: 161 start-page: 95 issue: 1 year: 2013 ident: 3217_CR3 publication-title: Br J Haematol doi: 10.1111/bjh.12225 – volume: 90 start-page: 193 issue: 3 year: 2015 ident: 3217_CR18 publication-title: Am J Hematol doi: 10.1002/ajh.23901 – volume: 110 start-page: 3255 issue: 10 year: 2019 ident: 3217_CR29 publication-title: Cancer Sci doi: 10.1111/cas.14167 – volume: 26 start-page: 1211 issue: 6 year: 2012 ident: 3217_CR1 publication-title: Leukemia doi: 10.1038/leu.2011.351 |
| SSID | ssj0017047 |
| Score | 2.325742 |
| Snippet | This single-center retrospective study was performed in consecutive patients with acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic cell... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 69 |
| SubjectTerms | Acute lymphoblastic leukemia Adolescent Adult Chemotherapy Complications Disease-Free Survival Female Hematology Hematopoietic Stem Cell Transplantation - adverse effects Hepatic Veno-Occlusive Disease - etiology Humans Inotuzumab Ozogamicin - therapeutic use Leukemia Lymphatic leukemia Male Medicine Medicine & Public Health Middle Aged Minimal residual disease Monoclonal antibodies Oncology Original Article Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Recurrence Remission Remission (Medicine) Remission Induction Retrospective Studies Salvage Therapy - methods Stem cell transplantation Survival Targeted cancer therapy Transplantation Transplantation, Homologous - adverse effects Treatment Outcome Veno-occlusive disease Young Adult |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fi9QwEA56gvgi_rZ6SgTfNLhtk3bzJId4HML55MG-lXQylcW9ZrXtg_en-Nc6k2Z3kcN7bpqEzGTmSybzjRBvrdUePbYkAaiV7rBWbVWAAgtQWqdLX3O-8_nX6uxCf1mZVbpwG9Kzyp1NjIbaB-A78g-M9G2lTV1-3P5UXDWKo6uphMZtcYepy_jwVa_2B668XsQCYwtbGGXIlaakmTl1jnwb5ybzgyKC5Ur_65iuoc1rkdLogE4fiPsJOcqTWdQPxS3sH4m75yk2_lj8OZFALkmyTuEgQycTZ-og42ty9JIvXeW6D-N0NV26Voar8J3r0a97SdhVOphGlJvfJODQEqqmgeQGpx94uXaSk162A3USq4pLjteT7iE1ibSvYRvWnA8pORJAAzJl-sbNeU39E3Fx-vnbpzOVKi8oEpAdVe5d65yzSPBMA-ZIZgBa7_IatOkcmHZRAPBxyCMy_QzkGozNiw4XFRhTPhVHfejxuZDaeOZCXnbOdrpaGkcGw5Mh6Lg0J4HLTOS7ZW8g0ZJzdYxNcyBUZlE1JKomiqrRmXi3_2c7k3Lc2Pp4J80mbdChOahTJt7sP9PW4lVyPYaJ2piarB8d4m0mns1asB-u1NoSMl1m4v1OLQ6d_38uL26ey0txr-D0injFcyyOxl8TviLQM7avo2b_BZeU_3c priority: 102 providerName: ProQuest |
| Title | A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation |
| URI | https://link.springer.com/article/10.1007/s12185-021-03217-4 https://www.ncbi.nlm.nih.gov/pubmed/34490598 https://www.proquest.com/docview/2619964573 https://www.proquest.com/docview/2570111339 |
| Volume | 115 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fa9swED7WFsZexrqf7tqgwd42Q2xLVvSYjbRlo2WMBbInI8vnEZraYbYf1j-lf-3uFDthdB3syQ-WJaO7033S6bsDeGuMLLDAnCTgdChL1GGexi50xrnEWJkUmvnOF5fp-Vx-WqhFTwprhtvuQ0jSr9Q7sht5I2YT8xUgAtKh3IMDRXt31ut5PN3GDvTYlxUbm1iFihxoT5X5ex9_uqM7GPNOfNS7ndMn8LjHi2K6EfAhPMDqKTy86CPiz-B2Khw5IsGahI2oS9FnSm2Ev0OOheCjVrGs6ra76a5tLuqb-gdXoV9WghCrsK5rUax-kVjrnLA0DSRW2F3h9dIKprqsG-rE1xIXHKUnjUNq4pO91ut6ySxIwef_NCAnSl_ZDZupeg7z09m3j-dhX28hJLGYNowKm1trDRIokw4jJON3eWEj7aQqrVP5OHaON0EFIiedcZF0ykRxiePUKZW8gP2qrvAVCKkKzoA8Ka0pZTpRlpaJgsy_5IKcBCkDiIZpz1yfjJxrYqyyXRplFlVGosq8qDIZwLvtN-tNKo5_tj4epJn1ZtlkvF00qVQ6CeDN9jUZFM-SrbDuqI3StObR1t0E8HKjBdvhEikN4dFJAO8Htdh1fv-_HP1f89fwKGaShT_oOYb99meHJwR92nwEe3qhR3AwPfv-eUbPD7PLL19HXv9_A09UAF4 |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Nb9NAEB1VqQRcEN8YCiwSnMAitnfj7AGhAq1S2kQItVJvZr0eo4jEG7At1P4UfgS_kRl_JEIVvfXs9a7leZ553tk3A_BCa5lhhilZwMa-zDH201FofautjbSRURaz3nk6G01O5KdTdboFf3otDB-r7H1i46gzZ3mP_A0zfT2SKo7erX743DWKs6t9C40WFod49ot-2cq3Bx_Jvi_DcH_v-MPE77oK-LS4rvwgM6kxRiNRD2kxQIK4TTMTxFaq3FiVDkNrmepniFxaxQbSKh2EOQ5HVnGXCHL52zIiqjCA7fd7s89f1nmLeNi0NBvqUPmKgncn02nFehRNWQ3NR5joR8CX_4bCC_z2Qm62CXn7t-Bmx1XFbguu27CFxR24Nu2y8Xfh966wFAQFoxhL4XLRVWktRXN-HTPB27xiXriqPq-XJhXu3H0zS75fEFsWxtYVisUZQcqlxONpIbHA-jsu50awzGZV0iRNH3PBJwQI7UhDmkKzbuXmrMAUnHugBblI-8K0SqriHpxciVXuw6BwBT4EIVXG1ZfHudG5HI2VIReVkevJuRko0VkPgv61J7YrhM79OBbJpoQzmyohUyWNqRLpwav1Pau2DMilo3d6ayadSyiTDYA9eL6-TB8zvyVToKtpjIrJ3wZRpD140KJgvVwkpSYuPPbgdQ-LzeT_f5ZHlz_LM7g-OZ4eJUcHs8PHcCNkcUezwbQDg-pnjU-IclXp0w7nAr5e9af1F8eFPxU |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB5VRaq4IN4EChgJThB1k9ib9QGhirJqKa04UGlvwbEnaMVuvJBEqP0p_BR-HTN57ApV9NZzHNvyfJ75bM8D4KXW0qHDnCRg01AWmIb5OLah1dYm2sjEpRzvfHI6PjyTH2dqtgV_hlgYdqscdGKrqJ23fEe-x0xfj6VKk72id4v4fDB9t_oRcgUpfmkdyml0EDnG8190fKveHh2QrF_F8fTDl_eHYV9hIKSJ6DqMnMmNMRqJhkiLERLcbe5MlFqpCmNVPoqtZdrvEDnNio2kVTqKCxyNreKKEaT-b6QJmU3aS-lsfdiL0lFb3GykYxUqMuN9wE4Xtkd2leOi2ZmJjgSh_NcoXmK6l15pW-M3vQ23etYq9juY3YEtLO_Czkn_Ln8Pfu8LS-ZQMJ6xEr4Qfb7WSrSe7OgEX_iKeenr5qJZmlz4C__NLPl_QbxZGNvUKBbnBC6fE6OngcQCm--4nBvBATerijppK5oL9hUg3CM1aVPO-pWfcyym4FcIGpDTtS9MF1NV3oeza5HJA9gufYmPQEjlOA_zpDC6kOOJMqSsHCmhgsuCErENIBqWPbN9SnSuzLHINsmcWVQZiSprRZXJAF6v_1l1CUGubL07SDPrlUOVbaAcwIv1Z9rWvEqmRN9QG5WS5o2SRAfwsEPBerhESk2seBLAmwEWm87_P5fHV8_lOezQhso-HZ0eP4GbMUd5tDdNu7Bd_2zwKXGvOn_WglzA1-veVX8BH4xB5Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+case+series+of+patients+treated+with+inotuzumab+ozogamicin+for+acute+lymphoblastic+leukemia+relapsed+after+allogeneic+hematopoietic+cell+transplantation&rft.jtitle=International+journal+of+hematology&rft.au=Izumi%2C+Akihiko&rft.au=Tachibana%2C+Takayoshi&rft.au=Ando%2C+Taiki&rft.au=Tanaka%2C+Masatsugu&rft.date=2022-01-01&rft.issn=0925-5710&rft.eissn=1865-3774&rft.volume=115&rft.issue=1&rft.spage=69&rft.epage=76&rft_id=info:doi/10.1007%2Fs12185-021-03217-4&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s12185_021_03217_4 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0925-5710&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0925-5710&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0925-5710&client=summon |